Literature DB >> 7882379

The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells.

A Thanhäuser1, A Böhle, B Schneider, N Reiling, T Mattern, M Ernst, H D Flad, A J Ulmer.   

Abstract

Previously we have described the induction of MHC-unrestricted killer cells against bladder tumour cells by bacillus Calmette-Guérin (BCG), termed BCG-activated killer (BAK) cells. In the present paper we deal with the accessory-cell requirement for the activation of BAK cells. We show that monocytes are required for activating BAK cells, since no cytotoxicity can be induced in the absence of monocytes. Therefore, these phagocytes may represent the first step during the activation cascade of BAK cells. Furthermore, the presence of CD4+ T cells was essential for generating BAK cells: depleting peripheral blood mononuclear cells of CD4+ cells prior to stimulation with BCG abolished the cytotoxicity against bladder tumour cells. Experiments with monoclonal antibodies (mAb) neutralizing the activity of either interleukin-2 (IL-2) or interferon gamma (IFN gamma) underlined the importance of these cytokines: both mAb blocked the induction of BAK cells. Since both cytokines are related to the so-called Th1 pattern of T cells, we consider the second step of the generation of BAK cells as follows: monocytes presenting antigens of BCG trigger Th1-like cells in a preferred manner. These Th1-like T cells secrete IL-2 and IFN gamma and, thus, activate the BAK effector cells. Since CD4+ cells are dominant in the cells infiltrating the bladder wall after intravesical instillation of BCG in vivo, we postulate an important role for the Th1 subpopulation. We further postulate that the occurrence of macrophages in this infiltrate seems to be significant in the maintenance of the relapse-free state of the patient.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882379     DOI: 10.1007/bf01520291

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  Density-dependent tumor cell death and reversible cell cycle arrest: mutually exclusive modes of monocyte-mediated growth control.

Authors:  J van der Bosch; S Rüller; D Horn; R Schumann; M Schlaak
Journal:  Exp Cell Res       Date:  1990-04       Impact factor: 3.905

2.  Oxpentifylline in endotoxaemia.

Authors:  P Zabel; D T Wolter; M M Schönharting; U F Schade
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

5.  Human monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals.

Authors:  P H Schur; D M Chang; P Baptiste; L C Uhteg; D C Hanson
Journal:  Clin Immunol Immunopathol       Date:  1990-10

6.  Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.

Authors:  M H Wang; H D Flad; A Böhle; Y Q Chen; A J Ulmer
Journal:  Immunol Lett       Date:  1991-03       Impact factor: 3.685

7.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

8.  The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.

Authors:  A M Jackson; S Prescott; S J Hawkyard; K James; G Chisholm
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.

Authors:  A Thanhäuser; A Böhle; H D Flad; M Ernst; T Mattern; A J Ulmer
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 10.  Non-antibody immunotherapy of cancer.

Authors:  P B Chapman; A N Houghton
Journal:  Curr Opin Immunol       Date:  1993-10       Impact factor: 7.486

View more
  7 in total

Review 1.  Microorganisms and cancer: quest for a therapy.

Authors:  A M Chakrabarty
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

Review 2.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

3.  Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.

Authors:  M Takashi; S Katsuno; H Yuba; S Ohshima; K Wakai; Y Ohno
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

4.  Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha.

Authors:  J L Haley; D G Young; A Alexandroff; K James; A M Jackson
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

5.  Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.

Authors:  M Ferro; G Di Lorenzo; M D Vartolomei; D Bruzzese; F Cantiello; G Lucarelli; G Musi; S Di Stasi; R Hurle; G Guazzoni; G M Busetto; A Gabriele; F Del Giudice; R Damiano; F Perri; S Perdona; P Verze; M Borghesi; R Schiavina; G L Almeida; P Bove; E Lima; R Autorino; N Crisan; A R Abu Farhan; M Battaglia; G I Russo; Vincenzo Ieluzzi; G Morgia; P De Placido; D Terracciano; A Cimmino; L Scafuri; V Mirone; O De Cobelli; S Shariat; Guru Sonpavde; C Buonerba
Journal:  World J Urol       Date:  2019-04-16       Impact factor: 4.226

6.  The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.

Authors:  E Reyes; J Carballido; L Manzano; L Moltó; C Olivier; M Alvarez-Mon
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

7.  Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.

Authors:  Aliye Soylu; Ali T Ince; Hakan Polat; Nurgul Yasar; Aydin Ciltas; Selvinaz Ozkara; Ali I Tasci
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-15       Impact factor: 3.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.